Evidence map›Paper›PMID 35322793›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2022

SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.

Danii L S Suijk, Michaël J B van Baar, Erik J M van Bommel, Zainab Iqbal, Merle M Krebber, Volker Vallon, Daan Touw, Ewout J Hoorn, Max Nieuwdorp, Mark M H Kramer and 3 more

2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02682563. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02682563 phase4completed

A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus

Ran2016Enrolled44Registered outcomes10Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Diabetic NephropathiesArmsDapagliflozin 10mg QD, Gliclazide 30mg QD
Open the trial in the graph
NCT05210517 phase4completed

Uric Acid Excretion Study: Open-label Randomised Cross Over Study

Ran2020Enrolled10Registered outcomes3Posted comparisons0ConditionsType 2 DiabetesArmsBenzbromaron, empagliflozin 25 mg, Empagliflozin 25 MG + benzbromarone 100 mg
Open the trial in the graph
3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Danii L S SuijkDiabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands d.suijk@amsterdamumc.nl.
Michaël J B van BaarDiabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Erik J M van BommelDiabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Zainab IqbalDiabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Merle M KrebberDepartment of Nephrology and Hypertension, University Medical Center, Utrecht, The Netherlands.
Volker VallonDivision of Nephrology and Hypertension, Department of Medicine, University of California San Diego, La Jolla, California.
Daan TouwDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
Ewout J HoornDepartment of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-8738-3571
Max NieuwdorpDepartment of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Mark M H KramerDiabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Jaap A JolesDepartment of Nephrology and Hypertension, University Medical Center, Utrecht, The Netherlands.
Petter BjornstadDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Daniël H van RaalteDiabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Amsterdam University Medical Centers · NLUniversity Medical Center Utrecht · NLErasmus MC · NLUniversity Medical Center Groningen · NLUniversity of California San Diego · USUniversity of Colorado Denver · US

Funding

Unraveling the Impact of Per- and Polyfluoroalkyl Substances on Early Kidney Injury in Adolescents with Obesity and DiabetesR01DK129211 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Petter Bjornstad · 2021 to 2026
$3.9M
Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes StudyK23DK116720 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI BJORNSTAD, PETTER · 2018 to 2022
$963k
NIDDK NIH HHS K23 DK116720NIDDK NIH HHS R01 DK129211
6 · The paper itself

Abstract

BACKGROUND AND

objectivesSodium-glucose transporter 2 (SGLT2) inhibitor-induced uric acid lowering may contribute to kidney-protective effects of the drug class in people with type 2 diabetes. This study investigates mechanisms of plasma uric acid lowering by SGLT2 inhibitors in people with type 2 diabetes with a focus on urate transporter 1. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted an analysis of two randomized clinical trials. First, in the Renoprotective Effects of Dapagliflozin in Type 2 Diabetes study, 44 people with type 2 diabetes were randomized to dapagliflozin or gliclazide for 12 weeks. Plasma uric acid, fractional uric acid excretion, and hemodynamic kidney function were measured in the fasted state and during clamped euglycemia or hyperglycemia. Second, in the Uric Acid Excretion study, ten people with type 2 diabetes received 1 week of empagliflozin, urate transporter 1 blocker benzbromarone, or their combination in a crossover design, and effects on plasma uric acid, fractional uric acid excretion, and 24-hour uric acid excretion were measured.

resultsIn the Renoprotective Effects of Dapagliflozin in Type 2 Diabetes study, compared with the fasted state (5.3±1.1 mg/dl), acute hyperinsulinemia and hyperglycemia significantly reduced plasma uric acid by 0.2±0.3 and 0.4±0.3 mg/dl (both

conclusionsIn conclusion, SGLT2 inhibitors induce uric acid excretion, which is strongly linked to urinary glucose excretion and is attenuated during concomitant pharmacologic blockade of urate transporter 1. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Renoprotective Effects of Dapagliflozin in Type 2 Diabetes (RED), NCT02682563; SGLT2 Inhibition: Uric Acid Excretion Study (UREX), NCT05210517.

Indexed as

Diabetes Mellitus, Type 2HyperglycemiaSodium-Glucose Transporter 2 InhibitorsBenzbromaroneGlucoseHumansHypoglycemic AgentsKidneySodium-Glucose Transporter 2Uric AcidBenzbromaroneGlucoseHypoglycemic AgentsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsUric AcidkidneySGLT-2 inhibitiontype 2 diabetesURAT-1uric acid

Identifiers

PMID35322793
PMCPMC9269569
OpenAlexW4220823683

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.